Core - Laboratory Program

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 1U01CA072157-03
• Application #: 2826431
• Budget Start: 1996-10-01
• Budget End: 1997-09-30
• Support Year: 3
• Fiscal Year: 1997

Institution

• Name: Parker Hughes Institute
• City: St. Paul
• State: MN
• Country: United States
• Zip Code: 55113

Publications

Uckun, F M; Messinger, Y; Chen, C L et al. (1999) Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 5:3906-13

Vassilev, A; Ozer, Z; Navara, C et al. (1999) Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 274:1646-56

Chen, C L; Levine, A; Rao, A et al. (1999) Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies. J Clin Pharmacol 39:1248-55

Uckun, F M; Narla, R K; Zeren, T et al. (1998) In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clin Cancer Res 4:1125-34

Ek, O; Yanishevski, Y; Zeren, T et al. (1998) In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate. Leuk Lymphoma 30:389-94

Messinger, Y; Yanishevski, Y; Ek, O et al. (1998) In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates. Clin Cancer Res 4:165-70

Uckun, F M; Narla, R K; Jun, X et al. (1998) Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin Cancer Res 4:901-12